Highlights

  • Acrux has expanded its licensing agreement for Lenzetto in the Australian market with partner Gedeon Richter Plc.
  • Total milestone payments under the amended agreement could reach up to AUD 5.4 million.
  • Payments include upfront, regulatory and commercial milestone components.
  • Gedeon Richter will oversee registration of Lenzetto with Australia’s Therapeutic Goods Administration (TGA).
  • Lenzetto is already marketed in more than 40 countries globally and generated EUR 50 million in sales during 2025.
  • The therapy is expected to help address ongoing shortages of Menopause Hormone Therapy (MHT) products in Australia.

Acrux Limited (ASX:ACR) has provided additional details regarding its expanded licensing agreement for Lenzetto in Australia, offering further clarity on the timing and structure of milestone payments tied to the product’s planned local rollout. The update follows the company’s announcement that milestone payments under the amended agreement with long-term partner Gedeon Richter Plc could total up to AUD 5.4 million.

Acrux (ASX:ACR) shares were trading flat at AUD 0.013 during the afternoon session on 29 May 2026. Despite limited movement during the session, the stock has gained 44.44% over the past five trading days, although it remains down 35.00% over the past year. The subdued session movement may reflect some degree of short-term profit taking following the recent rally after the company’s Lenzetto licensing announcement.

Additional Milestone Details Clarify Payment Structure

In its follow-up release dated 29 May 2026, Acrux outlined how the milestone payments attached to the amended licensing agreement are expected to be received.

According to the company, the first payment will consist of an upfront signing milestone payable within 14 days following execution of the amendment.

The second milestone payment is linked to regulatory approval and becomes receivable once Marketing authorisation is secured from the Therapeutic Goods Administration (TGA) for the Australian market.

The final commercial milestone payment will become payable based on whichever occurs first between two specified triggers:

  • Achievement of a cumulative sales target
  • The second anniversary following product launch

Gedeon Richter Plc will be responsible for managing the Australian registration process for Lenzetto.

While the detailed commercial terms remain confidential, Acrux confirmed that the total potential milestone value under the amended agreement could reach AUD 5.4 million within two years from launch.

Australian Launch Targets Menopause Therapy Supply Gap

The amended agreement is expected to support the introduction of Lenzetto into the Australian market at a time when the country continues to face shortages of several Menopause Hormone Therapy products.

Lenzetto is a transdermal Estradiol spray designed for women experiencing symptoms associated with oestrogen deficiency following menopause. The therapy is used to help manage symptoms such as hot flushes and forms part of hormone replacement therapy treatment Options.

Acrux stated that the upcoming Australian availability of Lenzetto could help improve access to menopause-related treatment options for patients affected by ongoing supply constraints.

The product uses the company’s Patchless Patch™ transdermal drug delivery technology, which was originally developed at Monash University. The technology enables Estradiol to be delivered through a topical spray rather than conventional patches or oral administration.

According to the company, the delivery platform has already supported international commercialisation across multiple markets.

Lenzetto Already Established Across Global Markets

Although the latest agreement focuses on Australia, Lenzetto already has a significant international presence through Acrux’s Partnership with Gedeon Richter.

The product is currently marketed in more than 40 countries globally and generated sales of approximately EUR 50 million during 2025, according to the company.

This existing commercial footprint appears to provide a degree of validation for the product ahead of its planned Australian launch.

The agreement also further extends Acrux’s long-standing relationship with Gedeon Richter Plc, a pharmaceutical company headquartered in Hungary with a broad focus on women’s healthcare, neuropsychiatry and general medicines.

Founded in 1901, Richter reported 2025 sales of EUR 2.3 billion and maintains a Market Capitalisation of approximately EUR 4.8 billion.

Under the amended arrangement, Richter will continue to manage the commercialisation and regulatory responsibilities associated with Lenzetto in Australia.

Management Highlights Financial and Strategic Importance

Acrux management described the expanded agreement as beneficial from both commercial and strategic standpoints.

CEO and Managing Director John Warmbrunn said the arrangement could provide advantages for Australian women seeking additional menopause treatment options while also supporting Acrux’s financial position through future milestone receipts.

Management indicated that the anticipated milestone payments may assist the company as it continues progressing its Female Testosterone product pipeline.

The company also noted that bringing the locally developed therapy into the Australian market had remained a key objective for some time.

In addition, Acrux Product Development and Technical Affairs Director Felicia Colagrande highlighted the potential convenience and usability benefits associated with the Patchless Patch™ technology platform.

Acrux Continues Focus on Specialty Pharmaceutical Development

Acrux operates as a specialty pharmaceutical company focused on the development and commercialisation of topically applied pharmaceutical products.

The company has more than 25 years of experience in transdermal drug delivery systems and has previously commercialised products through licensing partnerships across international markets, particularly in the United States.

Its Business model has historically relied on partnering with larger pharmaceutical groups to commercialise products developed using its proprietary delivery technologies.

The latest Lenzetto expansion agreement appears consistent with that strategy, combining milestone-based licensing arrangements with international commercial partnerships.

In recent years, Acrux has also been advancing additional products targeting women’s healthcare markets, including its Female Testosterone therapy candidate.

Market Watching Regulatory and Commercial Milestones

With additional details around the milestone structure now disclosed, investors are likely to focus on the timing of key regulatory and commercial developments.

The next major step will involve progress toward TGA marketing authorisation, which is being managed by Gedeon Richter.

Attention may also turn toward the timing of the product launch in Australia and whether Lenzetto can establish market traction amid existing Demand for menopause hormone therapies.

The milestone-based structure additionally means future payments to Acrux are tied not only to regulatory approval but also to commercial performance following launch.

For investors, the agreement potentially provides exposure to near-term milestone payments while also positioning the company within a therapeutic area that continues to attract growing healthcare attention globally.

At the same time, the company’s broader performance may continue to depend on execution across its product development pipeline and future commercial licensing outcomes.

What the Update Could Mean for Acrux

The latest announcement does not materially change the overall Economics of the original agreement disclosed on 28 May 2026, but it does provide additional transparency around how and when milestone payments are expected to flow to Acrux.

The clarification around payment timing, regulatory responsibilities and commercial triggers may help investors better understand the pathway toward potential future Revenue associated with the Australian launch.

The update also reinforces management’s focus on expanding the reach of existing products while leveraging established licensing relationships with international pharmaceutical partners.

With Lenzetto already generating international sales and now preparing for potential Australian entry, the product may remain an important area of focus for the market over the coming quarters.